Resources:

Find resources by:

Sort by:

Date Resource A-Z Random

Resources from the last:

Box size:

Filer text box:

Topic familiarity:

Grid Layout:

Collections that use this topic:

Collection topics:

Adrenal Bone Cardiovascular Diabetes Endocrine-Disrupting Chemicals Endocrine-Related Cancer Metabolism Neuroendocrinology Obesity Reproduction Steroid and Steroidogenesis Thyroid

Bone Schlerostin

Vitamin D Schlerostin Calcium Mineral Skeletal Osteo Wnt Growth Plate

Resource not read: Query You and Your Hormones

Osteoporosis: Advances in treatment

Bone and Calcium Endocrine Network

Endocrinologist 151 Final

Endocrinologist 154 Web Version

Patients with new onset diabetes after liver transplantation have higher sclerostin levels that tend to decrease after an oral glucose tolerance test

Bone mass, sclerostin and body composition in women with anorexia nervosa: a 3-year follow-up after weight gain therapy

Bone matrix mineralization after sclerostin antibody treatment in a mouse model of osteogenesis imperfecta

Modulation of sclerostin expression by estrogen <em>via</em> BMP-2 signaling in human mesenchymal stromal cells and osteoblasts

Up-regulation of Wnt antagonists contributes to the attenuated response of bone formation to repeat doses of sclerostin antibody in a mouse model

Sclerostin blockade and zoledronic acid improve bone mass and strength in mice with exogenous hyperthyroidism

Role of Wnt antagonists (sclerostin and Dkk-1) on bone turnover markers and bone mass, in patients with complete spinal cord injury: preliminary results

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Evaluating novel bone biomarkers (FGF2, lipocalin, sclerostin) in patients with tumor induced osteomalacia (TIO) and acromegaly

Sclerostin but not Dickkopf-related protein 1 predicts bone mass and markers of bone turnover in older adults

Bisphosphonate treatment of postmenopausal osteoporosis and circulating levels of DKK1 and sclerostin: effects of treatment regimens

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

The decreased plasma levels of sclerostin but not Dickkopf-1 are associated with increased risk of osteoporotic fracture and lower bone mineral density in Korean postmenopausal women

Effects of sclerostin antibody and maintenance of new bone induced by sclerostin antibody in animal models

Sclerostin/MEPE axis in OA: lessons from long bone development

Effects of a mutated sclerostin peptide on bone and lean mass in mice

Bone matrix mineralization after sclerostin antibody treatment in a mouse model of osteogenesis imperfecta

Levels of scerostostin in serum and femoral vascular tissue and its relationship with atherosclerosis and cardiovascular mortality in patients with and without type 2 diabetes

Sex steroids as determinants of Wnt-Signalling markers in men

BMP to the bone

Increased Levels of Bone Formation and Resorption Markers in Patients with Hypophosphatemic Rickets

The effects of recombinant human TSH on selected bone markers in the follow-up of patients treated for differentiated thyroid carcinoma

New bone-forming treatments for osteoporosis

Impact of Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections on Bone Health in Children and Adolescents with Type 1 Diabetes

Canonical Wnt signaling in bone health and disease

Lower Bone Mineral Density in Type 1 Diabetes Mellitus (T1DM) is Probably Associated with Wnt/β-Catenin Pathway Downregulation Through Increased Dickkopf-1 Levels

Wnt and PTH signalling influences bone formation and metabolism

Serum levels of Wnt-signalling parameters poorly reflect bone mass and metabolism in healthy boys and men

Acute effects of glucocorticoids on CRP and bone markers

Influence of GH and/OR IGF-1 concentrations on selected bone turnover markers in children with different short stature etiology

Bone mass and biomarkers in young women 3 years after intensive nutrition therapy for severe anorexia nervosa

Functional hypoparathyroidism is a risk factor for bone fragility of postmenopausal women with vitamin D insufficiency

The new endocrinology of osteocytes

Monogenic Bone Disorders as a Model for Novel Treatment of Osteoporosis

Changes in bone mineral density and biochemical markers of bone turnover in postmenopausal women with breast cancer initiating aromatase inhibitors therapy

Comparative effect of Denosumab vs Teriparatide on bone and energy metabolism

Liraglutide, a glucagon-like peptide-1 receptor agonist, improves bone mass and architecture in ovariectomised mice

Bone structure and fractures

The assessment of bone regulatory pathways in children with malignant bone tumors

Other emerging therapies

Canonical Wnt signaling in bone health and disease

Highlights in clinical bone research

Osteoporosis in ankylosing spondylitis

Analysis of Osteoblats Precursors in Girls with Turner Syndrome

Discovery of microRNA biomarkers in circulation and bone tissue from a type-2 diabetes mellitus rat model under different anti-osteoporotic treatments

Increased levels of Dickkopf-1 may indicate lower osteoblast signaling, predisposing to lower bone mineral density in children and adolescents with type 1 diabetes mellitus

Bone health in patients with type 2 diabetes mellitus

Type 1 diabetes mellitus may predispose to lower bone mineral density through lower osteoblast signaling from increased levels of Dickkopf-1

Association among oxidative stress, Wnt signaling and trabecular bone microstructure in osteoporosis and osteoarthritis

Bone metabolism in patients with anorexia nervosa and amenorrhea